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Abstract
Purpose: Inhibition of angiogenesis has shown clinical success in patients with cancer. Thus, imaging approaches that allow
for the identification of angiogenic tumors and the detection of response to anti-angiogenic treatment are of high clinical
relevance.
Experimental Design: We established an in vivo magnetic resonance imaging (MRI) approach that allows us to
simultaneously image tumor microvessel density and tumor vessel size in a NSCLC model in mice.
Results: Using microvessel density imaging we demonstrated an increase in microvessel density within 8 days after tumor
implantation, while tumor vessel size decreased indicating a switch from macro- to microvessels during tumor growth.
Moreover, we could monitor in vivo inhibition of angiogenesis induced by the angiogenesis inhibitor PTK787, resulting in a
decrease of microvessel density and a slight increase in tumor vessel size.
Conclusions: We present an in vivo imaging approach that allows us to monitor both tumor microvessel density and tumor
vessel size in the tumor. Moreover, this approach enables us to assess, early-on, treatment effects on tumor microvessel
density as well as on tumor vessel size. Thus, this imaging-based strategy of validating anti-angiogenic treatment effects has
high potential in applications to preclinical and clinical trials.
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Introduction
In the past years preclinical and clinical studies have
demonstrated the essential role of angiogenesis for initiation of
tumor growth [1,2]. Treatment strategies inhibiting angiogenic
processes mainly targeting the vascular endothelial growth factor
(VEGF) and its receptor (VEGFR) have been implicated in clinical
trials. Thus, non-invasive methods to visualize and to monitor
tumor angiogenesis, and its inhibition, respectively, are of high
clinical relevance.
Currently, dynamic contrast enhanced magnetic resonance
imaging (DCE-MRI) is in clinical use for the assessment of anti-
angiogenic treatment effects [3,4]. DCE-MRI represents an
indirect measure of angiogenesis since it mainly reflects leakage
of the vascular bed by measuring the transfer of contrast agent into
the interstitial space. Due to high VEGF levels within tumors
vascular leakage is increased in tumor microvessels. Thus, DCE
imaging is proposed to be an accurate marker to detect therapeutic
VEGF inhibition. Gadolinium-based contrast agents are mostly
used for DCE-MRI.
Dennie et al proposed the use of the ratio of gradient echo and
spin echo relaxation rate changes (DR*2/DR2) after injection of a
high molecular weight contrast agent to measure average
microvessel density within a voxel [5]. These authors found a
good correlation between the MRI derived in vivo data and
histology. Based on these findings Jensen and Chandra proposed
to map the ratio of Q=DR2/(DR*2)
2/3 and demonstrated that Q
is dependent on water diffusion but independent of the
concentration of the contrast agent [6]. Because of the
heterogeneity of diffusion within tumors and changes of diffusion
during tumor growth [7] we sought to establish a multi-echo spin
echo sequence that takes the tumor diffusion into account for the
determination of tumor microvessel density and tumor vessel size.
In this study, we present an in vivo MRI approach that allows
for simultaneous assessment of tumor microvessel density and
vessel size by the use of a superparamagnetic iron oxyde (SPIO) at
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approach by monitoring tumor angiogenesis and detecting
response to the VEGFR/PDGFR tyrosine kinase inhibitor
vatalanib in a NSCLC xenograft model in mice.
Materials and Methods
Cell Culture
We used the NSCLC cell line H1975 [8]. Cells were maintained
in RPMI 1640 supplemented with 10% heat inactivated fetal
bovine serum (FBS, Roche Diagnostics, Mannheim, Germany),
1% penicillin and 1% streptomycin (P/S, Life Technologies) at
37uC in a 5% CO2/95% air atmosphere.
Xenograft model
All animal procedures were in accordance with the German
Laws for Animal Protection and were approved by the local
animal committee and the local authorities (LANUV, Recklin-
ghausen, reference number: 8.87-50.10.31.08.331).
Tumors were generated by s. c. injecting 5610
6 H1975 tumor
cells into nu/nu athymic male mice as described recently [8]
(Janvier, Europe). In the first set, we longitudinally measured
animals on days 1 (n=4), 4 (n=6, 2 sacrificed for immunohis-
tochemistry), 8 (n=6, 2 sacrificed for immunohistochemistry), 14
(n=6, 2 sacrificed for immunohistochemistry), 21 (n=6, 2
sacrificed for immunohistochemistry) after tumor cell injections.
In the second set, animals were randomized into two groups,
vehicle treated (control) and vatalanalib (PTK787) treated. Vehicle
and PTK787 animals were studied on day 8 (start of treatment) 14,
and 21 after tumor cell implantation (vehicle n=6, PTK787 n=6;
2 sacrificed for immunohistochemistry on day 21). Mice were
treated daily by oral gavage of 75 mg/kg PTK787. PTK787 was
dissolved at 1% DMSO and 0.5% Tween 80 in distilled water. All
controls were dosed with the same volume of vehicle (1% DMSO
and 0.5% Tween 80).
Immunohistochemistry
After the last MRI measurements, animals were sacrificed and
s.c. tumors were extracted. Tumors were embedded in tissue
freezing medium (Jung, Nussloch, Germany) and cut in 10-mm
frozen sections. Hematoxylin Eosin staining on the tissue was
performed according to standard protocols. Microvessel density
was assessed with CD31 staining (1:50 dilution, Mat.-No. 550274,
BD Pharmingen
TM). CD31 positive endothelial cells or cell cluster
were counted. In order to determine the mean number of
microvessel density within the tumor, the number of CD31
positive cells was determined by 3 different areas with maximal,
moderate, and minimal endothelial density. The mean number of
microvessels was determined as (F1+F2+F3)/3.
Magnetic Resonance Imaging (MRI)
All experiments were performed on an experimental animal
scanner at 7T (Bruker BioSpec; Bruker) equipped with a gradient
set of 400 mT/m. Radio frequency (RF) irradiation and signal
detection was achieved with custom-built coils: a 8-cm-diameter
Helmholtz coil arrangement for RF excitation, and a 16 mm
diameter surface coil for signal detection.
To determine DR2 and DR2* maps multi slice multi spin echo
(MSME) and multi gradient echo (MGE) pulse sequences,
respectively, were performed before and after injection of iron
oxide nanoparticles (EndoremH, Guerbet Inc.) at a dose of 30 mg
Fe/kg. The postcontrast image acquisition was delayed by 2 min
to ensure a steady-state distribution of contrast agent in the
vascular network.
MSME and MGE MR images were obtained with the same
Field of View (FOV) (16 mm616 mm), and matrix size (64664),
and a slice thickness of 0.3 mm (Matrix size 25062506300 mm
2).
MSME was acquired with TR=5000 ms and TE=(10.9,
21.8,…,109)ms. MGE was acquired with TR=1400 ms and
TE=(4, 8,…,32) ms with a 60u hermite pulse.
To map the apparent diffusion coefficient (ADC) of water, two
diffusion-weighted images with b=300, b=800 s/mm
2, in both, x
and z directions of the gradient system were acquired, together with
a reference image (b<0s / m m
2) at the following parameters: voxel
size=0.560.2560.3 mm
3, zero-filled to 0.2560.2560.3 mm
3,
matrix 64664. The total scan time was 49 min and 16 seconds.
We started the measurement with the ADC map. Then, we
acquired the MSME and MGE pre CA-injection datasets. The post
injectionscan timewas 16 minand38 sec.Thesignalintensity after
contrast agent injection was stable within half an hour.
Data analysis
The co-registration of the images was performed using FSL
software (FLIRT, Oxford, UK). IDL was used for image
processing (Interactive data language, ITT, VIS). We used a
volume of interest (VOI) of the entire tumor to assess the global
values of the ADC, MDI and VSI. The in-house developed
software VINCI was used for volume of interest (VOI) analysis of
MR images [9].
The ADC map was calculated from the diffusion-weighted
images with a mono-exponential fit of the signal intensity of the
three different b values (b0, 300, 800 s/mm
2).












[10,11] and a modified calculation for multi-spin echo








[12] (j0 =Blood Volume fraction; dv=2pcDXB0=frequency
shift, #=number of 180u pulses; R=Vessel Size Index (VSI)
DX=changes in the susceptibility, B0=magnitude of the
magnetic field, c=gyromagnetic ratio). The prefactor 0.694 had
been calculated in [12].












As such, measurement values are independent of the local
contrast agent concentration. The process is schematically
depicted in Fig. 1.
The combination of equation (1) and (2) leads to the term of the
VSI
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Statistical tests were performed using SPSS software (release
18.0 SPSS, Inc., Chicago. IL.USA). To assess statistical signifi-
cance we used the Spearman correlation and the t-test. Statistical




Equation (2) considers the number of 180u-pulses (#) within the
MSME sequence. The calculation of the VSI map and the MDI
map are based on equation (2). To our knowledge, we take for the
first time the number of 180u-pulses into account by calculating
VSI and MDI maps.
Comparison of the image derived MDI values with
histology
Inordertovalidateourimage-deriveddataformicrovesseldensity
wecompared the MDIvaluesto theinvitromicrovesseldensity.The
in vitro microvessel density index was immunohistochemically
assessed by CD31 positive microvessels at different time points
directly after the MRI measurements. Here, we found a significant
correlation between the in vivo derived MDI values and the
microvessel density index of CD31 positive cells (r=0.8, p=0.0006;
Spearman correlation) (Fig. 2). Furthermore, tumor areas with high VSI
values showed also large vessel size in histology (Fig. 2A).
Monitoring tumor microvessel density and vessel size
We analyzed the growth of tumor microvessels as detected by
the MDI map from day 1 to day 4, 8, 14, and 21. Already one day
following s.c. inocculation of the tumor xenograft we observed
high intra- and subcutaneous MDI values around the tumor. On
day 4 we found an increasing number of tumor microvessels
within the tumor (MDI value: 198628). The maximum was
reached 8 days after tumor cell inocculation (MDI value: 297673).
The MDI values then slightly decreased at day 14 (247694) and
day 21 (230672). We did not find significant changes between day
1 and 4, day 4 and 8, day 8 and 14, day 14 and 2. Of note, at later
time points we found a rather homogeneous distribution of the
microvessels within the center as well as in the outer rim of the
tumor (Fig. 3). This was accompanied with a homogeneous, rather
low ADC value on days 14 and 21 (Fig. 3).
Using maps of the vessel size index (VSI) we estimated the vessel
diameter over time. Interestingly, we found inverse behavior of the
vessel size and vessel density changes: an increase in MDI from day 4
to day 14 was accompanied by a decrease in VSI, indicating a switch
from larger to smaller vessel sizes (VSI, day 4: 68.7640.8; day 14:
50.761.8). Tumor vessels with larger diameter were found in the
outer rim of the tumor with their diameter still increasing during the
following days (Fig. 3).
Figure 1. Schematic of data calculation for the microvessel density index (MDI) and the vessel size index (VSI).
doi:10.1371/journal.pone.0019592.g001
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a decline in extracellular diffusion, most probably due to an
increase in tumor cell density.
Response to PTK787 treatment
We determined the potential of our protocol to assess response
to anti-angiogenic treatment. Tumors were grown for 8 days and
MDI, ADC and VSI were measured. We then started PTK787
treatment and monitored response to treatment after 6 and 13
days by calculating percentage changes in MDI, VSI and ADC.
Already after 6 days of oral PTK787 treatment, we found a
significant decline in the MDI values in comparison to the vehicle
group (p=0.021) (see Table 1 and Fig. 4). This was confirmed
after 13 days of treatment (p=0.005). In contrast, the VSI
decreased in the control group over time whereas in the treated
tumors the VSI remained nearly stable at day 6 and even
increased till day 13. This indicates a switch from macro- to micro-
vessels in the vehicle group. On the other hand, PTK787
treatment induces the inverse effect resulting in a shift from
micro- to macrovessels.
In parallel we observed a decrease in the ADC value after 6
days of PTK787 treatment whereas there was nearly no change in
the ADC in the vehicle treated tumors. The ADC value then
increased till day 13 during PTK787 treatment (Tab. 1 and Fig. 4).
Discussion
In this study we demonstrate the feasibility to non-invasively
determine microvessel density in an experimental NSCLC model
by the use of the MRI derived MDI map. Moreover, we propose a
Figure 2. Comparison of the image derived values of MDI and VSI to CD31 positive endothelial cell staining. (A) a vehicle treated (upper
row) tumor presenting a high microvessel density index (MDI (1/mm
2)) in MRI and a low vessel index (VSI (mm)). The PTK787-treated tumor (lower row)
presents low MDI values with high VSI values. (B) correlation between CD31 positive vessels per area unit and the imaged derived MDI values (n=10).
doi:10.1371/journal.pone.0019592.g002
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(VSI) and tumor microvessel density (MDI). We show that the
values obtained by the MDI map reflect the microvessel density as
assessed by immunohistochemical CD31 staining. Most impor-
tantly, the MDI allows to monitor PTK787 induced reduction in
microvessel density as early as 6 days after start of treatment.
Finally, repetitive MR imaging reveals a shift of vessel diameter
toward larger lumen in PTK787 treated tumors in vivo.
Currently, there are numerous anti-angiogenic agents in clinical
trials ([14]; http://www.cancer.gov/clinicaltrials). Likewise, new
imaging modalities are required that allow to monitor tumor
microvessel density growth and the detection of anti-angiogenic
treatment effects. As reported previously, MR imaging offers the
detection of capillaries with a diameter of 10 to 30 mm, reflecting
the range of the diameter of tumor microvessels [6,10]. Jensen [15]
first proposed the Q-map for the assessment of microvessel density
in vivo. Based on this approach, Wu et al found reasonable Q-map
values within the healthy mouse brain when comparing the results
with histological analysis [16]. However, as indicated by Jensen in
2006 [15], the diffusion within the tissue affects the calculation of
microvessel density (cf. Eq. 3). This is particularly true for tumor
tissue since the diffusion within the tumor is highly variable.
Therefore, we established a new protocol for vessel density
imaging that includes the ADC map, to take the function of the
diffusion heterogeneity within the tumor into consideration for the
determination of the MDI. Herewith, we received a clear
improvement of the vessel density values, as demonstrated with
the significant correlation to the microvessel density assessed by
immunohistochemistry. Of note, the same calculation without the
ADC map showed no correlation to immunohistochemically
assessed by microvessel density (data not shown).
The theoretical description of Kiselev et al [11] has been made
for a single echo experiment. Nevertheless, multi echo experiments
were used to calculate the Q-maps or the VSI [17]. The gradients
for the 180 degree pulses induce diffusion weighting. By using
multi spin echo sequences this diffusion weighting is usually not
considered. Therefore, the calculation of delta R2 via the fitting on
multi echo sequences leads to incorrect results for the VSI and
MDI. Thus, we applied the correction factor as suggested by
Figure 3. Longitudinal investigation of vascular dynamics during tumor growth. Simultaneous in vivo monitoring of tumor depiction with
T2-weighted imaging, microvessel density (MDI), vessel size (VSI) and apparent diffusion coefficient (ADC) during tumor growth on day 1, day 4, day
8, day 14, and day 21 (D1, D4, D8, D14, D21).
doi:10.1371/journal.pone.0019592.g003
Table 1. Percent changes (relative to day 0) in T2, MDI, VSI
and ADC values after 6 days and 13 days of PTK787/vehicle
treatment.
PTK787 treated Vehicle treated
day 6 day 13 day 6 day 13
Mean SD mean SD mean SD mean SD
T2 24.79 3.85 20.93 16.85 25.69 5.08 222.55 16.85
MDI 2225.10 169.88 2199.52104.80 41.30 2.17 23.82 23.22
VSI 215.85 64.90 31.63 26.60 2194.2045.30 253.10 87.90
ADC 214.61 18.32 11.71 11.45 0.22 26.72 2.84 18.97
doi:10.1371/journal.pone.0019592.t001
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correction factor is considered in the formula (3) and (4) both the
second and the third echo can be used. However, by using further
180u-pulses we found an increase of the obtained MDI that did not
reflect the results from the immunohistochemistry. Thus, we
conclude that it is important to use a spin echo sequences with the
appropriate echo time to calculate the MDI and VSI.
We have presented a new strategy for the simultaneous
estimation of the vessel size index (VSI) and the microvessel density
index (MDI)by the useofa multispinecho sequence.With thistool,
we could demonstrate in vivo that in untreated tumors the decrease
in the mean tumor vessel size is paralleled by an increase in
microvessel density. These findings are in line with a study by Drevs
et al. [18] who observed a shift of vessel diameter toward larger
lumen in PTK787 treated tumors in comparison to the vehicle
group in vitro. This observation is reasonable since it reflects the
sprouting of smaller tumor microvessels from pre-existing larger
vessels during tumor growth that is inhibited by PTK787.
After 6 days of PTK787 treatment, we found a decrease in the
ADC value. It is well known that inhibition of VEGF/VEGFR2
results in a reduction in vascular permeability [19]. We hypothesize
that the PTK787 induced decline in vessel permeability reduces
interstitial edema and, thus, intra-tumoral diffusion that is reflected
by the observed decrease in ADC map. Moreover, after 13 days of
treatment there was again a slight increase in the ADC value most
probably due to necrotic tumor transformation [20,21,22,23].
Finally, we have demonstrated that the MDI method permits
the characterization of microvessel density in vivo in longitudinal
studies. Further, the MDI detected the PTK787 treatment
induced reduction of microvessel density as early as 6 days of
treatment. This is of high clinical interest since it allows for
monitoring effects of anti-angiogenic treatments based on the
growth and sprouting of tumor microvessels. Of note, the iron
oxide nanoparticle Endorem
R is a true intravascular contrast
agent with a long plasma half-life (T1/2.2.5 h) [24], already
approved for human use. Severe side effects have been reported
for the gadolinium based contrast agents [25]. Thus, Endorem
represents a highly promising contrast agent for clinical studies.
Moreover, using Gd-complexes the changes of the signal induced
by the susceptibility is weak. Since Endorem is a paramagnetic CA
the changes of the local susceptibility in the steady state is much
higher than induced by gadolinium complexes.
In summary, we present an in vivo imaging approach for
simultaneous monitoring of tumor microvessel density (MDI) and
tumor vessel size (VSI). This approach enables the early
assessment of treatment effects on microvessel density as well as
on tumor vessel size. Thus, this imaging method bears high
potential for monitoring anti-angiogenic treatment effects in
preclinical and clinical trials.
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